Literature DB >> 16217056

The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

Shelley L Hyman1, Arthur Shores, Kathryn N North.   

Abstract

OBJECTIVE: To assess the frequency and severity of specific cognitive deficits in children with neurofibromatosis type 1 (NF1) in a large unbiased cohort.
METHODS: Extensive cognitive assessments were performed in 81 children with NF1 ages 8 to 16 years and their performance was compared with that of 49 unaffected sibling controls.
RESULTS: Eighty-one percent of the children with NF1 had moderate to severe impairment in one or more areas of cognitive functioning. Although 51% of children with NF1 performed poorly on tasks of reading, spelling, and mathematics, specific learning disabilities (as defined by IQ-achievement discrepancies) were present in only 20% of the children. Sustained attention difficulties were present in 63% of children with NF1, with 38% of children with NF1 fulfilling the diagnostic criteria for attention deficit-hyperactivity disorder. The NF1 neuropsychological profile is characterized by deficits in perceptual skills (visuospatial and visuoperceptual), executive functioning (planning and abstract concept formation), and attention (sustained and switching). Interestingly, both verbal and visual memory was unaffected in NF1 children, and their memory skills were in general stronger than their level of general intellectual function. Although both expressive and receptive language skills were significantly impaired in NF1 children, they appeared to be relatively better preserved than visuospatial abilities once IQ is taken into account.
CONCLUSION: There is an extremely high frequency of cognitive problems in children with neurofibromatosis type 1, making cognitive dysfunction the most common complication to affect quality of life in these children.

Entities:  

Mesh:

Year:  2005        PMID: 16217056     DOI: 10.1212/01.wnl.0000179303.72345.ce

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  169 in total

Review 1.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 2.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

3.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

Review 4.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

5.  Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.

Authors:  Laura A Barquero; Angela M Sefcik; Laurie E Cutting; Sheryl L Rimrodt
Journal:  Dev Med Child Neurol       Date:  2015-04-22       Impact factor: 5.449

6.  ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.

Authors:  Yuan Wang; Edward Kim; Xiaojing Wang; Bennett G Novitch; Kazuaki Yoshikawa; Long-Sheng Chang; Yuan Zhu
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

7.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

8.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

10.  Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.

Authors:  Pamela L Wolters; Staci Martin; Vanessa L Merker; James H Tonsgard; Sondra E Solomon; Andrea Baldwin; Amanda L Bergner; Karin Walsh; Heather L Thompson; Kathy L Gardner; Cynthia M Hingtgen; Elizabeth Schorry; William N Dudley; Barbara Franklin
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.